NFSG
MBRX icon

Newbridge Financial Services Group’s Moleculin Biotech MBRX Stock Holding History

Newbridge Financial Services Group’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261 Hold
114
– – ﹤0.01% 1122
2025
Q4 		$377 Sell
114
-1
-0.9% -$9 ﹤0.01% 1121
2025
Q3 		$1.52K Hold
115
– – ﹤0.01% 1156
2025
Q2 		$866 Buy
115
+60
+109% +$1.23K ﹤0.01% 1214
2025
Q1 		$1.33K Hold
55
– – ﹤0.01% 924
2024
Q4 		$2.32K Hold
55
– – ﹤0.01% 952
2024
Q3 		$3.88K Hold
55
– – ﹤0.01% 524
2024
Q2 		$4.81K Buy
55
+28
+104% +$3.23K ﹤0.01% 853
2024
Q1 		$4.05K Buy
+27
New +$5.76K ﹤0.01% 915

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM

Newbridge Financial Services Group's MBRX Position: Q1 2026 in Review

Newbridge Financial Services Group held its Moleculin Biotech (MBRX) position steady in Q1 2026 at 114 shares worth $261. The position accounts for ﹤0.01% of the portfolio, ranked #1122.

Newbridge Financial Services Group first reported a position in MBRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.81K in Q2 2024. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Newbridge Financial Services Group held 114 shares of Moleculin Biotech worth $261 as of Q1 2026.
  • Newbridge Financial Services Group left its Moleculin Biotech share count unchanged in Q1 2026.
  • Moleculin Biotech made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q1 2026, its #1122 holding.
  • Newbridge Financial Services Group first reported a position in Moleculin Biotech in Q1 2024 and has held it in 9 quarters since.
  • Newbridge Financial Services Group's Moleculin Biotech position peaked at $4.81K in Q2 2024.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Newbridge Financial Services Group's 13F filing for Q1 2026, filed 5 May 2026.